MX2020008205A - Derivado de biarilo, metodo de preparacion del mismo y uso farmaceutico del mismo. - Google Patents

Derivado de biarilo, metodo de preparacion del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2020008205A
MX2020008205A MX2020008205A MX2020008205A MX2020008205A MX 2020008205 A MX2020008205 A MX 2020008205A MX 2020008205 A MX2020008205 A MX 2020008205A MX 2020008205 A MX2020008205 A MX 2020008205A MX 2020008205 A MX2020008205 A MX 2020008205A
Authority
MX
Mexico
Prior art keywords
preparation
diseases
pharmaceutical application
biaryl derivative
biaryl
Prior art date
Application number
MX2020008205A
Other languages
English (en)
Inventor
Hongping Yu
Zhui Chen
Yaochang Xu
Fei Yang
Yongxian Zhang
Haiyan Ying
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of MX2020008205A publication Critical patent/MX2020008205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Se describen un derivado de biarilo, con la estructura de la fórmula (I) y una actividad que inhibe la interacción PD-1/PD-L1, un método de preparación del mismo, y una aplicación farmacéutica del mismo. La serie de compuestos de la presente invención se puede aplicar ampliamente en la preparación de un fármaco para prevenir y/o tratar cánceres o tumores, enfermedades y alteraciones relacionadas con el sistema inmunitario, enfermedades contagiosas, enfermedades infecciosas o enfermedades metabólicas mediados por una vía deseñalización PD-1/PD-L1, y se muestra prometedora para el desarrollo de una nueva generación de inhibidores de PD-1/PD-L1.(ver fórmula I).
MX2020008205A 2018-02-05 2019-01-29 Derivado de biarilo, metodo de preparacion del mismo y uso farmaceutico del mismo. MX2020008205A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810111413 2018-02-05
CN201810770644 2018-07-13
PCT/CN2019/073594 WO2019149183A1 (zh) 2018-02-05 2019-01-29 一种联芳基衍生物、其制备方法和在药学上的应用

Publications (1)

Publication Number Publication Date
MX2020008205A true MX2020008205A (es) 2020-09-18

Family

ID=67479570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008205A MX2020008205A (es) 2018-02-05 2019-01-29 Derivado de biarilo, metodo de preparacion del mismo y uso farmaceutico del mismo.

Country Status (13)

Country Link
US (1) US11459339B2 (es)
EP (1) EP3750887A4 (es)
JP (1) JP7033343B2 (es)
KR (1) KR102534185B1 (es)
CN (1) CN111448189A (es)
AU (1) AU2019214089B2 (es)
BR (1) BR112020014459A2 (es)
CA (1) CA3088927C (es)
MX (1) MX2020008205A (es)
PH (1) PH12020551184A1 (es)
SG (1) SG11202006409TA (es)
TW (1) TWI828649B (es)
WO (1) WO2019149183A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7185532B2 (ja) 2016-06-27 2022-12-07 ケモセントリックス，インコーポレイティド 免疫調節化合物
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. USEFUL INDANE-AMINES AS AN AGONISTS OF PD-L1
US20210040118A1 (en) * 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
SG11202112310TA (en) 2019-05-15 2021-12-30 Chemocentryx Inc Triaryl compounds for treatment of pd-l1 diseases
JP2022536845A (ja) 2019-06-20 2022-08-19 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の治療のための化合物
JP2022539830A (ja) 2019-07-10 2022-09-13 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１阻害剤としてのインダン
US20220380342A1 (en) * 2019-07-18 2022-12-01 Abbisko Therapeutics Co., Ltd. Biphenyl derivatives for blocking pd-1/pd-l1 interaction, preparation method therefor and use thereof
PE20221764A1 (es) 2019-10-16 2022-11-11 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
WO2021147940A1 (zh) * 2020-01-21 2021-07-29 上海华汇拓医药科技有限公司 一种pd-1/pd-l1抑制剂及其制备方法和用途
CN113248492B (zh) * 2020-02-10 2022-11-08 上海海雁医药科技有限公司 杂环取代的含氮六元杂环衍生物及其制法与医药上的用途
CN113493469A (zh) * 2020-03-18 2021-10-12 成都倍特药业股份有限公司 可作为免疫调节剂的化合物、其制备方法和应用
CN114075123B (zh) * 2020-08-11 2023-06-06 中国人民解放军军事科学院军事医学研究院 苄胺类衍生物及其制备方法与用途
EP4159720A1 (en) 2021-09-30 2023-04-05 Recepton Spolka z Ograniczona Odpowiedzialnoscia Nonsymmetric substituted 1,1'-biphenyl derivatives and uses thereof
WO2023169373A1 (zh) * 2022-03-07 2023-09-14 上海和誉生物医药科技有限公司 一种全对称联苯基衍生物及其制备方法和应用
CN117343006A (zh) * 2023-10-08 2024-01-05 河南科技大学 一种arb-272572的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102276644B1 (ko) * 2013-09-04 2021-07-13 브리스톨-마이어스 스큅 컴퍼니 면역조절제로서 유용한 화합물
EP3390361B1 (en) * 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
CA3028685A1 (en) * 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3029857C (en) 2016-07-05 2023-07-04 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109195602B (zh) 2016-08-03 2022-01-07 上海齐鲁制药研究中心有限公司 用作免疫调节剂的对称或半对称化合物
ES2941716T3 (es) * 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US20180179179A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof

Also Published As

Publication number Publication date
WO2019149183A1 (zh) 2019-08-08
SG11202006409TA (en) 2020-08-28
US20210032270A1 (en) 2021-02-04
AU2019214089A1 (en) 2020-07-09
CN111448189A (zh) 2020-07-24
TW201934544A (zh) 2019-09-01
KR102534185B1 (ko) 2023-05-18
RU2020127950A (ru) 2022-03-11
CA3088927C (en) 2023-03-21
BR112020014459A2 (pt) 2020-12-15
CA3088927A1 (en) 2019-08-08
JP7033343B2 (ja) 2022-03-10
TWI828649B (zh) 2024-01-11
EP3750887A1 (en) 2020-12-16
EP3750887A4 (en) 2021-10-20
KR20200100717A (ko) 2020-08-26
RU2768830C2 (ru) 2022-03-24
AU2019214089B2 (en) 2021-02-11
JP2021512878A (ja) 2021-05-20
RU2020127950A3 (es) 2022-03-11
PH12020551184A1 (en) 2021-05-10
US11459339B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
PH12020551184A1 (en) Biaryl derivative, preparation method thereof and pharmaceutical application thereof
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
NZ750414A (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP4269440A3 (en) Composition for treating il-6-related diseases
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12015502425B1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
NZ726695A (en) Gls1 inhibitors for treating disease
ZA202206266B (en) Pd-l1 antagonist compound
MX2021009170A (es) Cristal de compuesto de diariltiohidantoina.
AU2016248387A8 (en) Preparation and use of kinase inhibitor
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.